S2Medical AB (S2M) - Cash Flow Conversion Efficiency
Based on the latest financial reports, S2Medical AB (S2M) has a cash flow conversion efficiency ratio of 0.068x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr676.00K ≈ $72.75K USD) by net assets (Skr9.88 Million ≈ $1.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See S2M equity financing ratio to measure how much of total assets are equity-financed.
S2Medical AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how S2Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check S2M operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
S2Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of S2Medical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
STMicroelectronics NV
LSE:0INB
|
0.221x |
|
Keramika Indonesia Assosiasi
JK:KIAS
|
0.007x |
|
Galileo Tech Ltd
TA:GLTC
|
0.023x |
|
Upsellon Brands Holdings Ltd
TA:CHR
|
0.180x |
|
Reliance Industries Limited
IL:RIGD
|
N/A |
|
Trade & Value AG
HM:TAV
|
N/A |
|
Onfolio Holdings Inc
NASDAQ:ONFO
|
0.000x |
|
Cobra Resources PLC
LSE:COBR
|
-0.060x |
Annual Cash Flow Conversion Efficiency for S2Medical AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of S2Medical AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of S2Medical AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.88 Million ≈ $1.06 Million |
Skr675.00K ≈ $72.64K |
0.068x | -83.97% |
| 2024-12-31 | Skr11.80 Million ≈ $1.27 Million |
Skr5.03 Million ≈ $541.40K |
0.426x | +104.28% |
| 2023-12-31 | Skr1.66 Million ≈ $178.42K |
Skr-16.52 Million ≈ $-1.78 Million |
-9.964x | -150.39% |
| 2022-12-31 | Skr7.07 Million ≈ $760.76K |
Skr-28.13 Million ≈ $-3.03 Million |
-3.979x | -197.08% |
| 2021-12-31 | Skr14.68 Million ≈ $1.58 Million |
Skr-19.67 Million ≈ $-2.12 Million |
-1.339x | -244.25% |
| 2020-12-31 | Skr32.77 Million ≈ $3.53 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.389x | +42.87% |
| 2019-12-31 | Skr25.11 Million ≈ $2.70 Million |
Skr-17.10 Million ≈ $-1.84 Million |
-0.681x | -132.57% |
| 2018-12-31 | Skr43.55 Million ≈ $4.69 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.293x | +63.05% |
| 2017-12-31 | Skr7.38 Million ≈ $793.67K |
Skr-5.85 Million ≈ $-629.12K |
-0.793x | +28.05% |
| 2016-12-31 | Skr2.75 Million ≈ $296.05K |
Skr-3.03 Million ≈ $-326.18K |
-1.102x | -- |
About S2Medical AB
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more